Utilization of B12 for the treatment of chronic migraine
Copyright © 2020. Published by Elsevier Ltd..
Chronic migraine is a particular classification of a headache that is typically unilateral and pulsatile and lasts for at least 3 months. Owing to its high prevalence and detrimental impact on personal, social, and economic aspects of patient lives, much desire has gone into fully understanding the pathogenesis of migraine, and to search for therapeutic agents. In addition to current therapeutics such as triptans, ergotamine, and monoclonal antibodies targeting calcitonin gene-related peptide receptors, vitamin B12 has been investigated for its possible use as a prophylactic agent for migraines. Specifically, the observed effects of vitamin B12 on nitric oxide and homocysteine prompt further investigation of its underlying mechanisms in migraine pathophysiology. In this comprehensive review, we provide a brief overview of migraines and current therapies while focusing on the promising role of vitamin B12 as a possible treatment option for chronic migraine management.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
---|---|
Enthalten in: |
Best practice & research. Clinical anaesthesiology - 34(2020), 3 vom: 06. Sept., Seite 479-491 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Urits, Ivan [VerfasserIn] |
---|
Links: |
---|
Themen: |
0LVT1QZ0BA |
---|
Anmerkungen: |
Date Completed 01.06.2021 Date Revised 01.06.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.bpa.2020.07.009 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315745657 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM315745657 | ||
003 | DE-627 | ||
005 | 20231225155600.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.bpa.2020.07.009 |2 doi | |
028 | 5 | 2 | |a pubmed24n1052.xml |
035 | |a (DE-627)NLM315745657 | ||
035 | |a (NLM)33004160 | ||
035 | |a (PII)S1521-6896(20)30064-1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Utilization of B12 for the treatment of chronic migraine |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.06.2021 | ||
500 | |a Date Revised 01.06.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020. Published by Elsevier Ltd. | ||
520 | |a Chronic migraine is a particular classification of a headache that is typically unilateral and pulsatile and lasts for at least 3 months. Owing to its high prevalence and detrimental impact on personal, social, and economic aspects of patient lives, much desire has gone into fully understanding the pathogenesis of migraine, and to search for therapeutic agents. In addition to current therapeutics such as triptans, ergotamine, and monoclonal antibodies targeting calcitonin gene-related peptide receptors, vitamin B12 has been investigated for its possible use as a prophylactic agent for migraines. Specifically, the observed effects of vitamin B12 on nitric oxide and homocysteine prompt further investigation of its underlying mechanisms in migraine pathophysiology. In this comprehensive review, we provide a brief overview of migraines and current therapies while focusing on the promising role of vitamin B12 as a possible treatment option for chronic migraine management | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a chronic migraine | |
650 | 4 | |a headache | |
650 | 4 | |a homocysteine | |
650 | 4 | |a hydroxocobalamin | |
650 | 4 | |a migraine | |
650 | 4 | |a vitamin B12 | |
650 | 7 | |a Homocysteine |2 NLM | |
650 | 7 | |a 0LVT1QZ0BA |2 NLM | |
650 | 7 | |a Vitamin B Complex |2 NLM | |
650 | 7 | |a 12001-76-2 |2 NLM | |
650 | 7 | |a Nitric Oxide |2 NLM | |
650 | 7 | |a 31C4KY9ESH |2 NLM | |
650 | 7 | |a Vitamin B 12 |2 NLM | |
650 | 7 | |a P6YC3EG204 |2 NLM | |
700 | 1 | |a Yilmaz, Melis |e verfasserin |4 aut | |
700 | 1 | |a Bahrun, Ehab |e verfasserin |4 aut | |
700 | 1 | |a Merley, Caitlin |e verfasserin |4 aut | |
700 | 1 | |a Scoon, Logan |e verfasserin |4 aut | |
700 | 1 | |a Lassiter, Grace |e verfasserin |4 aut | |
700 | 1 | |a An, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Orhurhu, Vwaire |e verfasserin |4 aut | |
700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical anaesthesiology |d 2002 |g 34(2020), 3 vom: 06. Sept., Seite 479-491 |w (DE-627)NLM122752538 |x 1878-1608 |7 nnns |
773 | 1 | 8 | |g volume:34 |g year:2020 |g number:3 |g day:06 |g month:09 |g pages:479-491 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bpa.2020.07.009 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 34 |j 2020 |e 3 |b 06 |c 09 |h 479-491 |